Skip to content
Exclusive CEO Interviews
Press Release

Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting

Affinia Therapeutics will present new AFTX-201 preclinical data, the UPBEAT Phase 1/2 trial design, and proprietary capsid engineering and manufacturing advancements across two oral and four poster sessions at ASGCT 2026 in Boston, May 11-15.

Press Releases
8 min read
Table of Contents
Corporate Overview

Affinia Therapeutics

About Affinia Therapeutics ▼
Affinia Therapeutics is a clinical-stage biotech company pioneering a transformational treatment paradigm shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics' pipeline of first-in-class or best-in-class product candidates, initially in cardiovascular diseases, leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models. For more information, visit affiniatx.com.
About BAG3 DCM ▼
BAG3 dilated cardiomyopathy (DCM) is a serious, inherited heart condition with a high mortality rate and a significant unmet medical need. The disease affects more than 70,000 patients in Canada and the E.U., U.K., and U.S. regions. The BAG3, or Bcl2-associated athanogene 3, gene encodes for a protein that is critical to the normal structure and function of heart cells. Patients with BAG3 DCM have a mutation in the BAG3 gene and a deficiency in functional BAG3 protein, resulting in early onset heart failure that progresses rapidly. Despite current standard of care, almost 25% of patients require a heart transplant.
About AFTX-201 ▼
AFTX-201 is a potential best-in-class investigational genetic medicine for the treatment of BAG3-associated DCM. AFTX-201 is designed to deliver a fully human, full-length BAG3 transgene using Affinia's proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than those associated with gene therapies using conventional capsids such as AAV9 or AAVrh74. AFTX-201 is given as a simple one-time intravenous (IV) administration. AFTX-201 increased BAG3 protein levels in the heart and fully restored cardiac function in an animal model of BAG3 DCM. The U.S. FDA has accepted Affinia's IND application for AFTX-201 and granted it Fast Track designation. The European Medicines Agency has granted Orphan Drug designation, and Health Canada has granted Clinical Trial Application approval to advance the UPBEAT trial in Canada.
Clinical Program

The UPBEATⓂ Clinical Trial

The UPBEATⓂ clinical trial is a multicenter, single-arm open-label Phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with genetically confirmed BAG3-associated dilated cardiomyopathy. The trial includes a dose-exploration phase followed by a dose-expansion phase. All participants will receive a single intravenous infusion of AFTX-201 at a dose that has been deemed safe and efficacious based on preclinical studies.
The primary objective of the trial is to evaluate safety and tolerability through 52 weeks following administration. Secondary and exploratory objectives include pharmacodynamic and preliminary efficacy assessments, which will be evaluated as changes from baseline. Study design, dose selection, and monitoring plans are informed by input from patients, clinicians, and regulators and by completed nonclinical proof-of-concept, biodistribution, and safety studies, which demonstrated complete correction of heart ejection fraction to normal (wild type) level and adequate safety margin for the doses being explored in the clinical trial.
Protocol-defined stopping rules, centralized safety data review, and oversight by an independent Data Safety Monitoring Board are implemented to ensure the safety of participants. Multiple trial sites across the U.S. and Canada are planned to be available. Travel arrangements can be made for interested participants not living near a trial site.
Clinical Trial Inquiries

UPBEAT Trial Enrollment

Affinia Therapeutics
Interested participants who have a BAG3 mutation, are 18–55 years old, and not able to perform normal activities are encouraged to reach out to the trial team.
Email the UPBEAT Team

Apr 28, 2026

Affinia Therapeutics to present new AFTX-201 preclinical data and the UPBEATⓂ Phase 1/2 trial design at ASGCT 2026

Two oral and four poster presentations will showcase AFTX-201 for BAG3-associated dilated cardiomyopathy, a CNS-penetrant engineered capsid (ATC-134), and Affinia's high-yield AAV manufacturing process at the American Society of Gene & Cell Therapy 2026 Annual Meeting in Boston, May 11–15, 2026.

WALTHAM, Mass. – April 28, 2026 – Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that it will present new preclinical data on the company's lead program AFTX-201, as well as highlight the design of the Phase 1/2 UPBEATⓂ clinical trial investigating AFTX-201 in patients with BAG3-associated dilated cardiomyopathy (DCM), and Affinia's proprietary capsid engineering and high-yield manufacturing process, in several oral and poster sessions at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held May 11-15, 2026 in Boston, MA and virtually.

AFTX-201 is a potential best-in-class investigational genetic medicine for the treatment of BAG3-associated DCM. AFTX-201 is designed to deliver a fully human, full-length BAG3 transgene using Affinia's proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than those associated with gene therapies using conventional capsids such as AAV9 or AAVrh74. The safety and efficacy of AFTX-201 as a treatment for people living with BAG3 DCM is being investigated in the UPBEAT clinical trial. AFTX-201 is given as a simple one-time intravenous (IV) administration. AFTX-201 increased BAG3 protein levels in the heart and fully restored cardiac function in an animal model of BAG3 DCM.

The U.S. Food and Drug Administration has accepted Affinia's Investigational New Drug (IND) application for AFTX-201 and granted it Fast Track designation during the first quarter of 2026. In addition, the European Medicines Agency has granted Orphan Drug designation to Affinia for AFTX-201 and the company recently received Clinical Trial Application approval from Health Canada to advance the UPBEAT clinical trial in Canada.

"We look forward to unveiling new preclinical data on AFTX-201, our lead program for BAG3-associated DCM, and the design of our Phase 1/2 UPBEAT clinical trial as well as advancements in our blood brain barrier-penetrant capsids and our high-yield manufacturing process at this year's ASGCT Annual Meeting. The data being presented showcases our scientific progress and readiness for clinical testing of AFTX-201, affirming Affinia's commitment to delivering potentially curative genetic therapies for people living with devastating diseases."

— Rick Modi, Chief Executive Officer, Affinia Therapeutics

Two oral presentations will showcase AFTX-201 preclinical data and Affinia's proprietary manufacturing process for AFTX-201. Affinia will also hold four poster presentations. The first poster provides an overview of the design of the UPBEAT Phase 1/2 clinical trial evaluating AFTX-201 in patients with BAG3-associated DCM. The second poster describes the development, optimization, and qualification of a comprehensive product-specific analytical panel for AFTX-201 that also sets the foundation for the development of additional product candidates. The company will also present a poster showcasing new results that further validate the central nervous system (CNS) transduction potential of ATC-134, Affinia's novel engineered AAV capsid which exhibits widespread CNS expression in more than 90% of neurons after IV dosing in nonhuman primates. Lastly, the company will present preclinical data on an investigational gene therapy, developed through a collaboration with Modalis Therapeutics, which has the potential to be a best‑in‑class treatment for Myotonic Dystrophy Type 1.

The oral and poster presentation details are provided below. Abstracts can be found at annualmeeting.asgct.org. Data from the oral presentations are embargoed until 6:00 am ET on the presentation day.

Oral presentations

DetailInformation
TitleProcess development, technology transfer, clinical manufacturing, and process characterization of AFTX-201, an investigational new medicine for the treatment of BAG3-associated dilated cardiomyopathy
PresenterMatt Edwards, Vice President, Technical Operations, Affinia Therapeutics
SessionScale-up, scale-out, formulation, supply chains, quality, and logistics I
Date/TimeWednesday, May 13, 2026, 4:30–4:45 pm ET
LocationWestin Seaport Commonwealth Ballroom ABC (Concourse Level)
Abstract Number248
DetailInformation
TitleAFTX-201: A novel investigational AAV gene therapy for the treatment of BAG3-associated dilated cardiomyopathy
PresenterGiri Murlidharan, Ph.D., Senior Director of Translational Biology, Affinia Therapeutics
SessionGene therapy for cardiovascular disease
Date/TimeThursday, May 14, 2026, 3:45–4:00 pm ET
LocationMCEC Room 206AB (Level 2)
Abstract Number381

Poster presentations

DetailInformation
TitleStudy design of a phase 1/2 multicenter, open-label, dose-exploration and dose-expansion trial of AFTX-201 in adults with BCL-2 associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (UPBEAT trial)
PresenterCharles Cram, Senior Director of Clinical Operations, Affinia Therapeutics
Date/TimeWednesday, May 13, 2026, 5:00–6:30 pm ET
LocationExhibit Hall
Abstract Number2363
DetailInformation
TitleDevelopment, technology transfer, and qualification of product-specific methods for AFTX-201, an investigational new medicine for the treatment of BAG3-associated dilated cardiomyopathy
PresenterShahrzad Parker, Ph.D., Senior Scientist, Affinia Therapeutics
Date/TimeWednesday, May 13, 2026, 5:00–6:30 pm ET
LocationExhibit Hall
Abstract Number2215
DetailInformation
TitleEngineered AAV capsid achieves robust transduction in non-human primate central nervous system after low dose systemic administration
PresenterKyle Chamberlain, Ph.D., Senior Scientist, Affinia Therapeutics
Date/TimeWednesday, May 13, 2026, 5:00–6:30 pm ET
LocationExhibit Hall
Abstract Number2026
DetailInformation
TitlePairing AAV genome and capsid engineering of an epigenetic-editing modality to develop a best-in-class treatment for Myotonic Dystrophy Type 1 (DM1)
PresenterKeith Connolly, Ph.D., Associate Director, Modalis Therapeutics
Date/TimeTuesday, May 12, 2026, 5:00–6:30 pm ET
LocationExhibit Hall
Abstract Number1492

Source: Affinia Therapeutics

Comments

Related

Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease

Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease

BELMONT, Mass. – March 23, 2026 – Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced new clinical and neuroimaging data from an ongoing Phase 1b/2a study evaluating its autologous dopaminergic neuron replacement therapy for